Exploring the Use of GLP-1-Based Interventions for Obesity: A Qualitative Analysis of ClinicalTrials.gov Data - PubMed
3 hours ago
- #GLP-1 agonists
- #clinical trials
- #obesity
- The study analyzed 227 completed interventional trials from ClinicalTrials.gov focused on GLP-1 receptor agonists for obesity, retrieved on October 18, 2025.
- Liraglutide was the most studied GLP-1 agent (86 trials), followed by semaglutide and tirzepatide (18 each), with most trials being Phase 3 or 4 and enrolling under 200 participants.
- Primary outcomes emphasized weight-related measures, but research trends show increasing focus on broader endpoints like hepatic, cardiometabolic, and inflammatory outcomes.
- A significant increase in completed trials was noted after 2018, coinciding with the introduction of newer GLP-1 analogues.
- The analysis highlights an evolution in obesity pharmacotherapy research from weight and glycemic control to more comprehensive metabolic and organ-specific benefits.